- Home
- PDM vs MNMD Comparison
PDM vs MNMD Comparison
Compare PDM & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDM
- MNMD
- Stock Information
- Founded
- PDM 1997
- MNMD 2019
- Country
- PDM United States
- MNMD United States
- Employees
- PDM N/A
- MNMD N/A
- Industry
- PDM Building operators
- MNMD Pharmaceuticals and Biotechnology
- Sector
- PDM Real Estate
- MNMD Health Care
- Exchange
- PDM Nasdaq
- MNMD Nasdaq
- Market Cap
- PDM 1.1B
- MNMD 960.2M
- IPO Year
- PDM N/A
- MNMD N/A
- Fundamental
- Price
- PDM $8.18
- MNMD $13.65
- Analyst Decision
- PDM Buy
- MNMD Strong Buy
- Analyst Count
- PDM 5
- MNMD 7
- Target Price
- PDM $9.40
- MNMD $26.71
- AVG Volume (30 Days)
- PDM 847.3K
- MNMD 2.2M
- Earning Date
- PDM 10-27-2025
- MNMD 11-06-2025
- Dividend Yield
- PDM 3.06%
- MNMD N/A
- EPS Growth
- PDM N/A
- MNMD N/A
- EPS
- PDM N/A
- MNMD N/A
- Revenue
- PDM $565,502,000.00
- MNMD N/A
- Revenue This Year
- PDM N/A
- MNMD N/A
- Revenue Next Year
- PDM N/A
- MNMD N/A
- P/E Ratio
- PDM N/A
- MNMD N/A
- Revenue Growth
- PDM N/A
- MNMD N/A
- 52 Week Low
- PDM $5.46
- MNMD $4.70
- 52 Week High
- PDM $11.12
- MNMD $13.86
- Technical
- Relative Strength Index (RSI)
- PDM 40.42
- MNMD 66.18
- Support Level
- PDM $7.99
- MNMD $12.11
- Resistance Level
- PDM $8.40
- MNMD $13.09
- Average True Range (ATR)
- PDM 0.21
- MNMD 0.89
- MACD
- PDM -0.09
- MNMD 0.04
- Stochastic Oscillator
- PDM 22.48
- MNMD 90.07
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).